A prodrug form of azilsartan
Related Products
Active Metabolite(s)
26091Azilsartan
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Azilsartan Medoxomil

Item No. 23805

Technical Information
Formal Name
1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylic acid, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
CAS Number
863031-21-4
Synonyms
  • TAK-491
Molecular Formula
C30H24N4O8
Formula Weight
Purity
≥98%
Formulation
A solid
DMSO: Slightly SolubleMethanol: Slightly Soluble
SMILES
CCOC1=NC2=CC=CC(C(OCC(O3)=C(C)OC3=O)=O)=C2N1CC4=CC=C(C5=C(C6=NOC(N6)=O)C=CC=C5)C=C4
InChi Code
InChI=1S/C30H24N4O8/c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26/h4-14H,3,15-16H2,1-2H3,(H,32,33,36)
InChi Key
QJFSABGVXDWMIW-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Azilsartan medoxomil is a prodrug form of azilsartan (Item No. 26091), a potent and selective angiotensin II receptor 1 (AT1) antagonist.1,2 Azilsartan medoxomil (0.1-10 mg/kg) reduces blood pressure and decreases plasminogen activator inhibitor 1 (PAI-1) levels in the plasma, left ventricle, and aortic wall in mice in a dose-dependent manner.2 It also inhibits the pressor response induced by angiotensin II (Item No. 17150) in normotensive rats (ID50 = 0.12 mg/kg) and reduces blood pressure and improves glucose infusion, a marker of insulin sensitivity, in spontaneously hypertensive rats.3 Azilsartan medoxomil also has more potent antiproteinuric effects in Wistar fatty rats than olmesartan medoxomil (Item No. 11614). Formulations containing azilsartan medoxomil have been used in the treatment of hypertension.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Ojima, M., Igata, H., Tanaka, M., et alIn vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J. Pharmacol. Exp. Ther. 336(3), 801-808 (2011).

    2. French, C.J., Zaman, A.K., and Sobel, B.E. The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques. J. Cardiovasc. Pharmacol. 58(2), 143-148 (2011).

    3. Kusumoto, K., Igata, H., Ojima, M., et alAntihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Eur. J. Pharmacol. 669(1-3), 84-93 (2011).